A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

NCT05221658 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

ESCC or Esophageal Adenosquamous Carcinoma

Interventions

DRUG: HLX07+HLX10+ Cisplatin+5-FU
DRUG: HLX07

Sponsor

Shanghai Henlius Biotech